Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 4(3)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT01606670Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease

Role: lead

NCT01673282Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Role: lead

NCT01724918Phase 2Terminated

Lacosamide IV and EEG/EKG (LIVE) Study

Role: collaborator

NCT02409433Phase 4Terminated

Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management

Role: collaborator

NCT01069419Completed

Observation of Treatment With Certolizumab Pegol in Daily Practice

Role: lead

NCT01098162Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

Role: lead

NCT01159691Completed

Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch

Role: lead

NCT00438451Phase 4Completed

Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs

Role: collaborator

NCT00242606Phase 3Completed

Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy

Role: collaborator

NCT00307450Phase 4Completed

Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease

Role: collaborator

All 10 trials loaded